A recent Spanish clinical study1 responds to concerns about the negative effect of pathogen reduction (PR) with methylene blue (MB) on COVID-19 convalescent plasma immunoglobulin (PCC) function.
The results support the performance of convalescent plasma (CCP) treated with methylene blue as at least as effective as the CCP treated with other pathogen reduction methods (Intercept with amotosalen, Mirasol with riboflavin). Its clinical effectiveness is accordingly confirmed based on tests conducted on one-hundred and seventy-five patients (ninety THERAFLEX MB-Plasma) hospitalized with pneumonia due to SARS-CoV-2.
At Macopharma, our THERAFLEX MB-Plasma system provides a simple and effective pathogen reduction procedure (methylene blue treatment) designed for single plasma units.
1Romera Martinez I, Bueno Cabrera JL, Domingo-Morera JM, Lopez Aguilar JC, Villegas Da Ros C, Garcia Erce JA, et al. Pathogen reduction with methylene blue does not have an impact on the clinical effectiveness of COVID-19 convalescent plasma. Vox Sang. 2023. https://doi.org/10.1111/vox.13406